OMER Stock Eyes Worst Day In Nearly 18 Months With European Yartemlea Setback, Paper Losses Hitting Shares
CEO Demopulos said the company is now shifting its near-term regulatory strategy outside the European Union.
Archived explainer. For the current picture see today's OMER page.
OMEROS CORP (OMER) is down -16.55% in the latest session. Our newswire has captured 18 stories on OMER across 9 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Omeros Corp (OMER) shares fell 16.55% to $13.92, marking the company’s worst single-day performance in nearly 18 months. The primary driver of the decline was a negative opinion from the European Committee for Medicinal Products for Human Use regarding narsoplimab, which prompted management to shift its near-term regulatory strategy outside the European Union.
The stock sold off following the announcement that the European regulatory body issued a negative opinion for narsoplimab. CEO Demopulos stated that the company is now focusing its immediate regulatory efforts on markets outside the European Union. This development coincided with the release of third-quarter 2026 financial results, which showed gross product revenue for YARTEMLEA rising 30% as the drug gained hospital access. Despite the revenue growth and a turn to positive operating cash flow, the regulatory setback weighed heavily on investor sentiment.
Coverage of the event was extensive, with 18 stories published by 9 sources in the last 36 hours. HC Wainwright & Co. reiterated its rating on the stock, maintaining a price target of $33. Cantor Fitzgerald also maintained a Buy rating with a $22 price target. The earnings call highlighted that while YARTEMLEA sales surged, the company faces financial challenges as detailed in its 10-Q filing.
The stock printed two fresh 52-week lows on November 17, 2026. Over the last eight sessions, the stock has declined 17.7%, moving from $16.92 to $13.92. The current price sits within the 52-week range of $6.59 to $21.24. Fundamentals show a market cap of $1.3 billion, a P/E ratio of 11.4, and a net margin of 324.9%. The stock carries a beta of 2.99, indicating high volatility relative to the broader market.
Insider activity has been predominantly selling over the last 90 days, with five sales totaling $2.1 million and no buys recorded. Recent Form 4 filings include sales by David J. Borges, VP of Finance and CAO, on September 22, 2026; Peter B Cancelmo, VP and GC, on August 28, 2026; and Arnold C Hanish, a Director, on August 26, 2026.
Investors will monitor the company’s execution of its new regulatory strategy outside the European Union. The next scheduled earnings date is not provided in the current data set, so coverage breadth and subsequent regulatory updates will be the primary metrics to track.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CEO Demopulos said the company is now shifting its near-term regulatory strategy outside the European Union.
YARTEMLEA gained hospital access as gross product revenue rose 30% this quarter.
Nov 16, 2026 / 09:30PM GMTOperator Good afternoon and welcome to today's earnings call for Omeros Corporation. (Operator Instructions) Please be advised that th
Anthropic’s public listing, expected on Wednesday, could top $1.4 trillion in valuation, stoking a key test for Wall Street's AI appetite.
More on OMER: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier OMER move explainers: 2026-11-18 · 2026-11-17 · 2026-10-16 · 2026-09-23 · 2026-09-22